GE Healthcare and Promosome Sign Licensing Agreement - - BioPharm International

ADVERTISEMENT

GE Healthcare and Promosome Sign Licensing Agreement



GE Healthcare and Promosome LLC, a synthetic biology company, have signed a licensing agreement, giving GE Healthcare exclusive rights to a new suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture. Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.

In-licensing of Promosome’s cell line development technologies will enable GE Healthcare to expand its offering with a cell-line generation service focused on delivering increased expression levels for hard-to-manufacture therapeutic proteins and improving manufacturing efficiency through increased protein yields.

GE Healthcare recently acquired Thermo Fisher’s HyClone cell culture media and sera business.

Source: GE Healthcare

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines

Click here